XML 53 R113.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details) $ in Millions | 3 Months Ended | 12 Months Ended
--- | --- | ---
Dec. 29, 2019 USD ($) | Sep. 29, 2019 USD ($) | Jun. 30, 2019 USD ($) | Mar. 31, 2019 USD ($) | Dec. 30, 2018 USD ($) | Sep. 30, 2018 USD ($) | Jul. 01, 2018 USD ($) | Apr. 01, 2018 USD ($) | Dec. 29, 2019 USD ($) | Dec. 30, 2018 USD ($) Segment | Dec. 31, 2017 USD ($) Segment
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers | $ 20,747 | $ 20,729 | $ 20,562 | $ 20,021 | $ 20,394 | $ 20,348 | $ 20,830 | $ 20,009 | $ 82,059 | $ 81,581 | $ 76,450
Identifiable Assets | 157,728 |  |  |  | 152,954 |  |  |  | 157,728 | 152,954 |
Gain (Loss) on Disposition of Assets |  |  |  |  |  |  |  |  |  | 1,200 | 1,300
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability |  |  |  |  |  |  |  |  | 151 | $ (156) | $ 87
Number of segments | Segment |  |  |  |  |  |  |  |  |  | 3 | 3
Acquisition related costs | 90 | 107 | 55 | 67 |  |  |  |  |  |  |
Restructuring charges | 251 | 128 | 142 | 90 | 227 |  | 176 |  | 266 | $ 251 | $ 309
After Tax Restructuring Charge | 214 | 106 | 116 | 75 | 190 | 162 | 152 | 81 |  |  |
Asset write-downs |  |  |  |  |  |  |  |  | 1,096 | 1,258 | 795
In-process research and development (Note 5) |  |  |  | 890 |  | 1,126 |  |  | 890 | 1,126 | 408
Litigation expense | 264 | 4,000 | 409 | 423 | 1,288 |  | 703 |  |  |  |
Gain from divestiture |  |  |  |  |  |  |  |  | 2,154 | 1,217 | 1,307
Unrealized Gain (Loss) on Securities | 350 | 89 | 148 | 158 |  |  |  |  |  |  |
Medical Devices |  |  |  |  |  |  |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | 25,963 | 26,994 | 26,592
Restructuring charges |  |  |  |  |  | 190 |  | 107 | 400 |  |
Asset write-downs |  |  |  |  |  |  |  |  |  |  | 200
Litigation expense |  |  |  |  |  |  |  |  | 400 | 1,700 | 1,100
Restructuring Charge, Net of Accrual Adjustment |  |  |  |  |  |  |  |  |  | 600 | 800
Gain from divestiture |  |  |  |  |  |  |  |  |  |  | 700
Consumer |  |  |  |  |  |  |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers | 3,567 | 3,469 | 3,544 | 3,318 | 3,536 | 3,415 | 3,504 | 3,398 | 13,898 | 13,853 | 13,602
Restructuring charges |  |  |  |  |  |  |  |  | 100 |  |
Litigation expense |  |  |  |  |  |  |  |  | 400 | 300 |
Gain from divestiture |  |  |  |  |  |  |  |  |  |  | 500
Pharmaceutical |  |  |  |  |  |  |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers | 10,548 | $ 10,877 | $ 10,529 | 10,244 | 10,190 | 10,346 | $ 10,354 | $ 9,844 | 42,198 | 40,734 | 36,256
Unrealized loss on securities |  |  |  |  |  |  |  |  |  | 200 |
Restructuring charges |  |  |  |  |  |  |  |  | 100 |  |
In-process research and development (Note 5) |  |  |  |  |  |  |  |  | 900 |  | 400
Litigation expense |  |  |  |  |  |  |  |  | 4,300 |  | 100
Research and Development Expense |  |  |  |  |  |  |  |  | 300 |  |
Property, Plant and Equipment |  |  |  |  |  |  |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Long-Lived Assets | 17,658 |  |  |  | 17,035 |  |  |  | 17,658 | 17,035 |
Other Intangible Assets |  |  |  |  |  |  |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Long-Lived Assets | 81,282 |  |  |  | 78,064 |  |  |  | 81,282 | 78,064 |
Ci:z Holdings Co. Ltd. | Consumer |  |  |  |  |  |  |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Gain (Loss) on Sale of Equity Investments |  |  |  | $ 300 |  |  |  |  | 300 |  |
Alios Biopharma Inc and XO1 Limited | Pharmaceutical |  |  |  |  |  |  |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
In-process research and development (Note 5) |  |  |  |  |  |  |  |  |  | 1,100 |
XO1 |  |  |  |  |  |  |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability |  |  |  |  |  | $ (184) |  |  |  | (200) |
Actelion |  |  |  |  |  |  |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Acquisition related costs |  |  |  |  |  |  |  |  | 200 | 200 | 800
Actelion | Pharmaceutical |  |  |  |  |  |  |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Acquisition related costs |  |  |  |  |  |  |  |  | 200 | 200 | 800
AMO | Medical Devices |  |  |  |  |  |  |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Acquisition related costs |  |  |  |  |  |  |  |  |  | 100 | 100
United States |  |  |  |  |  |  |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | 42,097 | 41,884 | 39,863
United States | Medical Devices |  |  |  |  |  |  |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | 12,384 | 12,837 | 12,824
United States | Consumer |  |  |  |  |  |  |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | 5,839 | 5,761 | 5,565
United States | Pharmaceutical |  |  |  |  |  |  |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | 23,874 | 23,286 | 21,474
Corporate, Non-Segment |  |  |  |  |  |  |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Other Non Long Lived Assets | 58,788 |  |  |  | 57,855 |  |  |  | 58,788 | 57,855 |
Corporate, Non-Segment | General Corporate |  |  |  |  |  |  |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Long-Lived Assets | 1,049 |  |  |  | 1,064 |  |  |  | 1,049 | 1,064 |
Identifiable Assets | 25,356 |  |  |  | 24,187 |  |  |  | 25,356 | 24,187 |
Operating Segments |  |  |  |  |  |  |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | 82,059 | 81,581 | 76,450
Long-Lived Assets | 97,891 |  |  |  | 94,035 |  |  |  | 97,891 | 94,035 |
Operating Segments | Medical Devices |  |  |  |  |  |  |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Identifiable Assets | 49,462 |  |  |  | 46,254 |  |  |  | 49,462 | 46,254 |
Operating Segments | Consumer |  |  |  |  |  |  |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Identifiable Assets | 26,618 |  |  |  | 25,877 |  |  |  | 26,618 | 25,877 |
Operating Segments | Pharmaceutical |  |  |  |  |  |  |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Identifiable Assets | 56,292 |  |  |  | 56,636 |  |  |  | 56,292 | 56,636 |
Unrealized Gain (Loss) on Securities |  |  |  |  |  |  |  |  | 600 |  |
Operating Segments | NIZORAL | Consumer |  |  |  |  |  |  |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Gain (Loss) on Disposition of Assets |  |  |  |  |  |  |  |  |  | 300 |
Operating Segments | PANCREASE | Pharmaceutical |  |  |  |  |  |  |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Gain (Loss) on Disposition of Assets |  |  |  |  |  |  |  |  |  | 200 |
Operating Segments | LifeScan | Medical Devices |  |  |  |  |  |  |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Gain (Loss) on Disposition of Business |  |  |  |  |  |  |  |  |  | 500 |
Operating Segments | United States |  |  |  |  |  |  |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | 42,097 | 41,884 | 39,863
Long-Lived Assets | 41,528 |  |  |  | 37,117 |  |  |  | 41,528 | 37,117 |
Operating Segments | Europe |  |  |  |  |  |  |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | 18,466 | 18,753 | 17,126
Long-Lived Assets | 48,015 |  |  |  | 51,433 |  |  |  | 48,015 | 51,433 |
Operating Segments | Western Hemisphere excluding U.S. |  |  |  |  |  |  |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | 5,941 | 6,113 | 6,041
Long-Lived Assets | 2,862 |  |  |  | 2,752 |  |  |  | 2,862 | 2,752 |
Operating Segments | Asia-Pacific, Africa |  |  |  |  |  |  |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | 15,555 | 14,831 | $ 13,420
Long-Lived Assets | $ 5,486 |  |  |  | $ 2,733 |  |  |  | $ 5,486 | $ 2,733 |
Wholesaler 1 | Sales Revenue, Net |  |  |  |  |  |  |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Concentration risk (as a percent) |  |  |  |  |  |  |  |  | 15.00% | 14.00% | 14.00%
Wholesaler 2 | Sales Revenue, Net |  |  |  |  |  |  |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Concentration risk (as a percent) |  |  |  |  |  |  |  |  | 12.00% | 11.00% | 10.00%
Wholesaler 3 | Sales Revenue, Net |  |  |  |  |  |  |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Concentration risk (as a percent) |  |  |  |  |  |  |  |  | 11.00% | 11.00% |
AdvancedSterilizationProducts |  |  |  |  |  |  |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Gain (Loss) on Disposition of Business |  |  |  |  |  |  |  |  | $ 2,000 |  |
AdvancedSterilizationProducts | Operating Segments | Medical Devices |  |  |  |  |  |  |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Gain (Loss) on Disposition of Business |  |  |  |  |  |  |  |  | $ 2,000 |  |

X
- Definition After Tax Restructuring Charge + References No definition available. + Details
Name: | jnj_AfterTaxRestructuringCharge
Namespace Prefix: | jnj_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Other non long lived assets. + References No definition available. + Details
Name: | jnj_OtherNonLongLivedAssets
Namespace Prefix: | jnj_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Restructuring Charge, Net of Accrual Adjustment + References No definition available. + Details
Name: | jnj_RestructuringChargeNetofAccrualAdjustment
Namespace Prefix: | jnj_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228 + Details
Name: | us-gaap_AssetImpairmentCharges
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 + Details
Name: | us-gaap_Assets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 25 -Paragraph 23 -URI http://asc.fasb.org/extlink&oid=84229725&loc=d3e1043-128460 + Details
Name: | us-gaap_BusinessCombinationAcquisitionRelatedCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 4 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=109250915&loc=d3e13531-108611 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109250915&loc=d3e13537-108611 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 + Details
Name: | us-gaap_GainLossOnDispositionOfAssets1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1B -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684 + Details
Name: | us-gaap_GainLossOnSaleOfBusiness
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The difference between the carrying value and the sale price of equity securities, not separately or otherwise categorized as trading or available-for-sale. This element includes investments in which the entity holds a small ownership stake (generally, less than 20% of the shares outstanding) and cannot exert significant influence. + References No definition available. + Details
Name: | us-gaap_GainLossOnSaleOfEquityInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 + Details
Name: | us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees. + References No definition available. + Details
Name: | us-gaap_LitigationSettlementExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599 + Details
Name: | us-gaap_NoncurrentAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + References No definition available. + Details
Name: | us-gaap_NumberOfOperatingSegments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentInProcess
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4(b)) -URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747 + Details
Name: | us-gaap_RestructuringCharges
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of unrealized gain (loss) recognized in the income statement on unsold other securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 + Details
Name: | us-gaap_UnrealizedGainLossOnSecurities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The increase (decrease), resulting in a loss, in the difference between the fair value and the carrying value, or in the comparative fair values, of securities held at each balance sheet date, that was included in earnings for the period. + References No definition available. + Details
Name: | us-gaap_UnrealizedLossOnSecurities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherIntangibleAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=jnj_CizHoldingsCo.Ltd.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=jnj_AliosBiopharmaIncandXO1LimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=jnj_XO1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=jnj_ActelionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=jnj_AMOMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_GeneralCorporateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=jnj_NIZORALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=jnj_PANCREASEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=jnj_LifeScanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=jnj_WesternHemisphereExcludingUSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=jnj_AsiaPacificAfricaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=jnj_Wholesaler1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=jnj_Wholesaler2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=jnj_Wholesaler3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_AdvancedSterilizationProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |